To master global trends in advanced biotechnology and pharmaceuticals, the ITRI is striving for leveraging its world-class engineering capabilities for biomedical research and technology development. ITRI established the Biomedical Engineering Center (BMEC) on July 1st, 1999 to conduct multidisciplinary biotechnologies and forward-looking projects. On January 1st, 2006, BMEC was renamed to be the Biomedical Engineering Research Laboratories (BEL) to better perform exploratory R&D and unearth new applications in innovative life science.
Research and Development
The Biomedical Engineering Research Laboratories (BEL) at ITRI is involved in three major focusing areas: Novel Therapeutics, Molecular Diagnostics, and Regenerative Medicine. Key research projects include molecular scaffold-based pharmaceuticals, IP-based herbal medicine, novel drug delivery system, microarray platforms and applications, nucleic acid-based diagnostics, proteomics-based biomarker development, enabling technology for cell therapy, and embryonic stem cell research.
BEL is actively in collaboration with medical centers, biotech industry as well as other institutions locally and globally. Clinical studies are currently being conducted in collaboration with universities and hospitals such as the National Taiwan University Hospital and the Veterans General Hospital in Taipei. Several joint research programs with international institutes in the United States, Canada, Australia, and other regions are also in progress.
If you are interested in any collaboration opportunities, please contact Dr. Jenny Chen (jenny.chen@itri.org.tw).
No comments:
Post a Comment